The announcement of the coronavirus vaccines from Pfizer, Moderna and Oxford is a hopeful sign for many. Nonetheless, there’s still a lot that we do not know about the coronavirus infection. However, researchers continue to work diligently to learn more about the SARS-CoV-2 virus, which causes the infection.
While the vaccines that have been made are not 100% effective, they are effective enough to help achieve herd immunity, which will assist in efforts to contain the virus that is spreading rapidly, overwhelming health-care facilities and killing without mercy.
Many private firms are looking into coronavirus treatments, including Revive Therapeutics (CSE: RVV) (OTC: RVVTF), a biotech firm that focuses on the research and development of remedies for infectious diseases and rare disorders. The company is among 20 firms conducting an FDA-approved phase 3 trial for a coronavirus treatment.
Coronavirus has numerous side effects that elicit different symptoms in different individuals. Revive Therapeutics is currently working on modifying bucillamine to target lung inflammation caused by the coronavirus. Bucillamine has been used for more than three decades to treat rheumatoid arthritis in South Korea and Japan, and is both an anti-inflammatory and anti-rheumatic drug. The drug had been repurposed in 2015 and 2016 during a clinical trial for gout.
Revive Therapeutics is the only firm that is currently researching more about bucillamine. The company intends to share the preliminary data it gathers once an analysis has been completed. Revive Therapeutics CEO Michael Frank explained that bucillamine had a strong safety profile and history.
Earlier in July, Revive obtained permission from the U.S. Food and Drug Administration (“FDA”) to carry out phase 3 of a double-blind random placebo-controlled clinical trial whose purpose was to assess the effectiveness and safety of bucillamine in patients who were diagnosed with mild to moderate cases of the coronavirus. Frank explained that the company is currently in the phase 3 study for coronavirus, treating the effects of the infectious virus.
The trials in question are being conducted in various sites across the United States, including Nevada, Florida, California and Texas. Revive hopes to extend these trials into Canada and Asia in the near future. Revive Therapeutics expects that, as part of the trial, more than 200 Americans will have received the treatment by the end of 2020.
Last week, University of California researchers released a study that supports the theory that bucillamine can decrease the side effects linked to the coronavirus.
Some leading companies are making inroads into other types of treatments for a wide range of symptoms and illnesses. A clear example is Pure Extracts Technologies Corp. (CSE: PULL), a Canadian plant-extraction company venturing into developing wellness and therapeutic products from psychedelics and different functional mushrooms.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) are available in the company’s newsroom at https://ibn.fm/PULL
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.